Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 April 2007

Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells

  • Hye-Young Park1,
  • Yoon-Kyung Jeon,
  • Hyun-Jin Shin,
  • Il-Jin Kim,
  • Hio-Chung Kang,
  • Sook-Jung Jeong,
  • Doo-Hyun Chung &
  • …
  • Chang-Woo Lee 

Experimental & Molecular Medicine volume 39, pages 195–204 (2007)Cite this article

  • 1601 Accesses

  • 42 Citations

  • Metrics details

Abstract

The BubR1 mitotic-checkpoint protein monitors proper attachment of microtubules to kinetochores, and links regulation of chromosome-spindle attachment to mitotic-checkpoint signaling. Thus, disruption of BubR1 activity results in a loss of checkpoint control, chromosomal instability caused by a premature anaphase, and/or the early onset of tumorigenesis. The mechanisms by which deregulation and/or abnormalities of BubR1 expression operate, however, remain to be elucidated. In this study, we demonstrate that levels of BubR1 expression are significantly increased by demethylation. Bisulfite sequencing analysis revealed that the methylation status of two CpG sites in the essential BubR1 promoter appear to be associated with BubR1 expression levels. Associations of MBD2 and HDAC1 with the BubR1 promoter were significantly relieved by addition of 5-aza-2'-deoxycytidine, an irreversible DNA methyltransferase inhibitor. However, genomic DNA isolated from 31 patients with colorectal carcinomas exhibited a +84A/G polymorphic change in approximately 60% of patients, but this polymorphism had no effect on promoter activity. Our findings indicate that differential regulation of BubR1 expression is associated with changes in BubR1 promoter hypermethylation patterns, but not with promoter polymorphisms, thus providing a novel insight into the molecular regulation of BubR1 expression in human cancer cells.

Similar content being viewed by others

Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

Article Open access 24 July 2024

Hypermethylation of PDX1, EN2, and MSX1 predicts the prognosis of colorectal cancer

Article Open access 15 February 2022

Deubiquitinase OTUD6A promotes breast cancer progression by increasing TopBP1 stability and rendering tumor cells resistant to DNA-damaging therapy

Article 29 June 2022

Article PDF

Author information

Authors and Affiliations

  1. Department of Molecular Cell Biology Center for Molecular Medicine Samsung Biomedical Research Institute Sungkyunkwan University School of Medicine, Suwon, 440-746, Korea

    Hye-Young Park

Authors
  1. Hye-Young Park
    View author publications

    Search author on:PubMed Google Scholar

  2. Yoon-Kyung Jeon
    View author publications

    Search author on:PubMed Google Scholar

  3. Hyun-Jin Shin
    View author publications

    Search author on:PubMed Google Scholar

  4. Il-Jin Kim
    View author publications

    Search author on:PubMed Google Scholar

  5. Hio-Chung Kang
    View author publications

    Search author on:PubMed Google Scholar

  6. Sook-Jung Jeong
    View author publications

    Search author on:PubMed Google Scholar

  7. Doo-Hyun Chung
    View author publications

    Search author on:PubMed Google Scholar

  8. Chang-Woo Lee
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Park, HY., Jeon, YK., Shin, HJ. et al. Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells. Exp Mol Med 39, 195–204 (2007). https://doi.org/10.1038/emm.2007.22

Download citation

  • Published: 01 April 2007

  • Issue date: 01 April 2007

  • DOI: https://doi.org/10.1038/emm.2007.22

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • Bub1 spindle checkpoint protein
  • colorectal neoplasms
  • DNA methylation
  • polymorphism, genetic

This article is cited by

  • BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways

    • Chen Yu Jiao
    • Qin Chao Feng
    • Xiang Cheng Li

    Cell Death & Disease (2021)

  • BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis

    • Ye Yang
    • Chunyan Gu
    • Min Wang

    Medical Oncology (2015)

  • Causes and consequences of aneuploidy in cancer

    • David J. Gordon
    • Benjamin Resio
    • David Pellman

    Nature Reviews Genetics (2012)

  • Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer

    • Jung Eun Shin
    • Su Hyung Park
    • Yeun Kyu Jang

    Molecules and Cells (2011)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2026 Springer Nature Limited